LDX - Lumos Diagnostics Holdings

[System]

Lumos Diagnostics is a fully integrated developer and manufacturer of rapid, point-of-care (POC) diagnostic solutions. Lumos' capabilities and technologies allow it to take a POC diagnostic test from the early stage of developing an initial product concept, through development, clinical validation and verification, and then to manufacture of the test at commercial scale.

Lumos develops and manufactures proprietary and in-licensed POC diagnostic tests for commercial sale through distributors under its Products division, and develops and manufactures POC diagnostic tests on behalf of clients under fee-based commercial contracts under its Commercial Services division.

In FY20, Lumos launched FebriDx®, a POC diagnostic test that is able to rapidly identify patients with a microbial infection and, if positive, determine if that infection is caused by a virus or bacteria. Lumos has already appointed distributors and commenced initial commercial sales of FebriDx® in target markets including the United Kingdom, Germany and Canada. An initial 510(k) submission for regulatory clearance for FebriDx® in the United States is currently under review with the US Food and Drug Administration (FDA) for the use of FebriDx® to differentiate viral from bacterial infection in patients with acute respiratory infections. Subject to approval from the FDA for FebriDx®, Lumos intends to launch the product into the United States market.

It is anticipated that LDX will list on the ASX during June 2021.

Welcome to Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective point-of-care diagnostic test solutions. Learn about our team, products, services, investment opportunities, latest news, and how we innovate at the point-of-care.

lumosdiagnostics.com

 

[Dona Ferentes]

Listing date	5 July 2021 #
Company contact details	https://lumosdiagnostics.com/ Ph: +61 3 9999 7729
Principal Activities	Development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests.
GICS industry group	TBA
Issue Price	$1.25
Issue Type	Ordinary Fully Paid Shares
Security code	LDX
Capital to be Raised	$63,000,000
Expected offer close date	23 June 2021
Underwriter	Fully underwritten. Wilsons Corporate Finance Limited and Bell Potter Securities Limited (Joint underwriters and Lead Managers)

 

[Dona Ferentes]

made it to market today

Opened at $1.50 and steadily down, to close at $1.31, still above the $1.25 IPO price

 

[Dona Ferentes]

It would be fair to say there aren't too many that put on 500 per cent on news.

And the news ... I'll leave it to the company to put their case:

So, the price action; closed near it's high today,

but was a long time coming, out of the float.

 

[greggles]

Good result but given LDX listed at $1.25 just two years ago, and bottomed out at 1c at the end of June, this is cold comfort for those who bought into the IPO.

Also not quite sure what this will mean in the long term for revenues but at least it's a step in the right direction.

 

[Telamelo]

It would be fair to say there aren't too many that put on 500 per cent on news.

View attachment 159087

And the news ... I'll leave it to the company to put their case:
View attachment 159088

So, the price action; closed near it's high today,
View attachment 159090
but was a long time coming, out of the float.
View attachment 159091

LDX has rocketed 1310% in past 2 day's! Wow ?

 

[peter2]

Well now's the time. LOL

 

[Swervin Mervin]

Anyone still watching LDX? Got some at 10, volume is massive, something has to be up